Modern therapy for pediatric acute lymphoblastic leukemia (ALL) is based on the principle of risk stratification. One of the most important laboratory features used to accurately risk stratify patients is the presence of specific chromosomal translocation within the leukemic blasts. In this paper, we describe a multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the accurate, sensitive, and rapid identification of chimeric transcripts encoded by the major risk-stratifying translocations of pediatric ALL. This assay will identify both the CML-and ALL-type BCR-ABL transcripts encoded by the t(9;22), all described variants of the E2A-PBX1 transcripts encoded by the t (1;19) , the MLL-AF4 transcripts encoded by the t(4;11), and all variants of TEL-AML1 encoded by the t(12;21). In addition, we have developed a reverse dot-blot detection system as an alternative to traditional post-PCR Southern blot analysis. Application of this combined assay to the analysis of 70 leukemic samples and five cell lines resulted in a complete concordance between this multiplex assay and individual PCR reactions. The characteristics of the multiplex assay suggest that its application to routine clinical screening will significantly improve the ability of clinical laboratories to accurate risk stratify pediatric ALL patients.
Introduction
Treatment for pediatric acute lymphoblastic leukemia (ALL) varies substantially among different clinical/biologic subsets of patients. For example, patients whose leukemic subtype responds to antimetabolite-based chemotherapy are typically spared more intensive and toxic treatments, whereas, those whose leukemia is unlikely to respond to this treatment are typically offered more aggressive therapeutic approaches. A biologic feature of the leukemic blast that has been demonstrated to be a strong predictor of treatment response is the presence of specific chromosome translocations. The first translocation shown to have prognostic significance was the t(9;22)(q34;q11), which is found in the leukemic blasts of 3-5% of pediatric ALL patients. [1] [2] [3] [4] In this translocation, the c-ABL gene is translocated from the distal long arm of chromosome 9 into the BCR gene of chromosome 22, resulting in the BCR-ABL chimeric gene. This translocation identifies a subgroup of pediatric ALL patients with an extremely poor prognosis. Four-year event-free survivals (EFS) of less than 10% have been observed and few long-term survivals have been reported. Therefore, patients whose leukemic blasts contain the t(9;22) are typically offered the option of bone marrow transplantation soon after remission is achieved.
A second translocation that identifies a high risk group of patients is the t(1;19)(q23;p13). 5, 6 This translocation is one of the more frequent seen in pediatric ALL and is identified in 5-7% of cases overall and in 25% of cases with a pre-B cell immunophenotype. The t(1;19) involves the E2A gene on chromosome 19 and the PBX1 gene on chromosome 1, and results in the generation of an E2A-PBX1 chimeric gene. 7, 8 Although this rearrangement is associated with a poor prognosis in patients treated with standard chemotherapy, results indicate that its adverse prognostic impact may be nullified with more aggressive therapy. 9, 10 The last group of chromosomal translocations known to confer a poor prognosis in pediatric ALL patients are translocations involving chromosome 11q23. [11] [12] [13] [14] [15] [16] [17] [18] [19] Rearrangements of the 11q23 gene have been detected in 7-10% of ALL and in as many as 80% of infant cases, depending on the series examined and methodology used. Over twenty different reciprocal chromosome bands participate in balanced 11q23 translocations; however, the t(4;11)(q21;q23) is the most common, accounting for approximately 60-70% of these cases. [11] [12] [13] [14] [15] The t(4;11) results in the formation of a chimeric gene consisting of a variable amount of the 5Ј portion of the MLL gene, located on chromosome 11q23, fused to the 3Ј portion of the AF4 gene from chromosome 4q21. 20, 21 The t(4;11) or other 11q23 translocations identifies a subgroup of patients with a high probability of failing standard treatment protocols. [11] [12] [13] [14] [15] [16] [17] [18] [19] In fact, current treatment protocols for infants with t(4;11)-containing ALL includes bone marrow transplantation when a suitable donor is available. Thus, identification of either the t(9;22), t(1;19), t(4;11), or other 11q23 translocations is essential for the accurate assignment of these patients to high intensity treatment with or without bone marrow transplantation.
In contrast, we and others have demonstrated that the 1995 t(12;21)(p13;q22) identifies a clinically distinct patient population with a favorable prognosis. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] This translocation is the most frequent genetic lesion in childhood ALL occurring in approximately 20-25% of the cases. In this translocation, the HLH domain of the TEL gene (also called ETV6) located on chromosome 12 is fused to the AML1 gene located on chromosome 21. 22, 23 Children whose leukemic blasts contain this genetic lesion have an excellent response to standard therapy with average 5-year EFS estimates of 91 ± 5%. Recent results, however, suggest that the prognosis may be influenced by the treatment used. 32, 33 Cytogenetic analysis has been the standard method for identifying these translocations; however, this approach is technically difficult and even in the best of hands, yields uninterpretable results in a substantial proportion of cases. Moreover, the use of molecular-based approaches to identify these genetic lesions has revealed cases that lack cytogenetic evidence of these translocations but express the encoded chimeric transcript. This is most prevalent with the t(12;21), which is not visible by routine cytogenetics in the majority of patients expressing TEL-AML1. [22] [23] [24] [25] [26] In addition, molecular-based assays can be performed successfully on a substantially higher percentage of cases than can cytogenetics, since they require minimal tissue and do not require mitotic cells. Thus, molecular approaches appear to be ideal for the routine identification of these risk-stratifying translocations, and their use should result in the accurate assignment of a substantially higher percentage of patients to the appropriate treatment protocols, when compared to traditional diagnostic methodologies.
Present RT-PCR assays for the detection of the fusion transcripts encoded by the t(9;22), t(1;19), t(4;11) and t(12;21) are labor intensive and require individual reactions for each translocation. Moreover, because of breakpoint diversity in the t(9;22), t(1;19) and t(12;21), several primer sets are needed for [34] [35] [36] [37] however, these assays do not detect all of the desired translocations. In this paper, we now describe an optimized set of oligonucleotides and reaction conditions that allow the simultaneous screening for the chimeric transcripts encoded by these risk-stratifying translocations. The chimeric transcripts detectable with this assay include the CML-and ALL-type BCR-ABL transcripts encoded by the t(9;22), all variants of the E2A-PBX1 transcripts encoded by the t (1;19) , the MLL-AF4 transcripts encoded by the t(4;11), and the TEL-AML1 variants encoded by the t(12;21). In addition, we have developed a reverse dot-blot read-out assay as an alternative to traditional post-PCR Southern blot analysis. This modification eliminates the need to use radioactivity and significantly shortens the assay turnaround time. Our data suggest that this multiplex assay coupled with the reverse dot-blot read-out is an effective and efficient approach for the routine clinical identification of the risk-stratifying translocations of pediatric ALL.
Materials and methods

Cell lines and patient samples
RT-PCR assays (standard and multiplex) for the CML t(9;22), t(1;19), t(4;11) and t(12;21) were established by using the leukemic cell lines K562, 38 697, 39 RS4;11 40 and REH, 41, 42 respectively, and the leukemic cell line HL60 43 as a negative control. The RT-PCR for the ALL t(9;22) chimeric message was established by using leukemic blasts from a patient with t(9;22)-containing ALL. Validation of the multiplex assay was performed by using leukemic blasts from 70 pediatric patients with ALL. This group included a selected series of 41 ALL patients comprising of five cases of CML t(9;22), five cases of ALL t(9;22), three cases of t(4;11), six cases of t(1;19), five cases of t(12;21), and 17 cases which did not have any of these translocations. Also included in the 70 cases were 29 consecutive diagnostic pediatric samples. Written informed consent was obtained from patients or their legal guardians and all studies were approved by our Institutional Review Board.
Standard PCR analysis
Total RNA was extracted with Purescript (Gentra, Minneapolis, MN, USA) and 1 g was reverse transcribed with 110 units of Moloney murine leukemia virus reverse transcriptase (RT) (BRL, Gaithersburg, MO, USA) in 1 × PCR reaction buffer (Perkin-Elmer-Cetus, Norwalk, CT, USA) containing 10.5 ng/l random hexamers, 132 M each dNTPs, 10.5 mM DTT, and 1.05 U/l RNasin. Standard PCR amplification was performed in 100 l of 1 × PCR reaction buffer (Perkin-ElmerCetus) containing 112 mol/l dNTPs (Perkin-Elmer-Cetus), 5% dimethylsulfoxide (DMSO), 2.5 U of Taq polymerase, and oligonucleotide primers at a final concentration of 0.075 mol/100 l. Thirty-five cycles of amplification were performed in a thermocycler with a step program consisting of 1 cycle of 94°C for 1 min, 54°C for 1 min, and 72°C for 1 min; 14 cycles of 94°C for 30 s, 54°C for 1 min, and 72°C for 1 min; 19 cycles of 94°C for 30 s, 54°C for 1 min, and 72°C for 2 min; and one cycle of 94°C for 30 s, 54°C for 1 min, and 72°C for 7 min.
Multiplex PCR analysis
After standard RNA extraction, a multiplex reverse transcription (RT) reaction was performed that included specific 3Ј oli-gonucleotide primers for each translocation (see Table 1 below). For each sample, 4 l of RNA (1-2 g) and 18 l of diethyl pyrocarbonate (DEPC)-treated water were heated at 95°C for 5 min, then placed in an ice bath for 2 min. After a brief centrifugation, RNA was reverse transcribed in a final volume of 41.8 l containing 1 × PCR buffer, 132 M each dNTPs, 10.5 mM DTT, and the specific RT primers at the following concentrations, 1.6 ng/l 9;22, 1.8 ng/l 4;11, 1.2 ng/l 1;19, 1.4 ng/l 12;21, 1.05 U/l Rnasin, and 5.26 U/l reverse transcriptase. Tubes were incubated for 1 h at 37°C, heated to 95°C for 7 min, and then rapidly cooled in an ice bath. Each sample was then split in half and PCR was performed in either a final volume of 100 l of 1 × PCR mix (see Standard PCR analysis section) containing abl control primers, abl 5Ј (5ЈTTC AGC GGC CAG TAG CAT CTG ACT T 3Ј) and abl 3Ј (5Ј AGA TAC TCA GCG GCA TTG 3Ј), or in 100 l of multiplex mix (1 × PCR buffer, 3.5 mM MgCl 2 , 0.84 mM each dNTP, 5% DMSO, 0.75 ng/l CML (9;22)5Ј, 1.5 ng/l ALL(9;22)5Ј, 1.5 ng/l (9;22)3Ј, 0.75 ng/l (4;11)5Ј, 0.75 ng/l(4;11)3Ј, 1.5 ng/l (1;19)5Ј, 1.5 ng/l (1;19)3Ј, 1.5 ng/l (12;21)5ЈA, 1.5 ng/l (12;21)5ЈB, 1.5 ng/l (12;21)3Ј, and 0.1 U/l Taq, see Table 1 for the sequence of the oligonucleotide primers). For the reverse dot-blot, PCR was performed as described above, but the oligonucleotide primers listed in Figure 2 (a) Schematic of the E2A and PBX1 proteins. The location of the two N-terminal activation domains (AD I and AD II) and the Cterminal basic helix-loop-helix (bHLH) and DNA binding domain (bHLH) of E2A are indicated. The major functional domain of PBX1, which is retained in the fusion, is the homeobox domain (homeo). (b) Chimeric products of the t(1;19). The three major fusion products that result from the t(1;19) are illustrated. The locations of the oligonucleotide primers and probes are shown, as is the expect size of the RT-PCR products. Table 1 were synthesized with biotin at the 5Ј end. Both sense and anti-sense primers were biotinylated (Center for Biotechnology, St Jude Children's Research Hospital, Memphis, TN). Samples were amplified in a touchdown program consisting of one cycle of 94°C for 1 min, 64°C for 1 min, 72°C for 1 min; one cycle of 94°C for 30 s, 63°C for 1 min, 72°C for 1 min; then for each subsequent cycle the annealing temperature was dropped one degree, keeping the time the same as that in the second cycle listed above. After the annealing temperature reached 51°C, then 29 cycles were run at 94°C for 30 s, 50°C for 1 min, 72°C for one min; then, one cycle at 94°C for 30 s, 50°C for 1 min, 72°C for 7 min. The mixes were then placed at 4°C.
Southern blot readout
All of the PCR products obtained through the standard individualized RT-PCR reactions, as well as a subset of the products obtained through the multiplex assay, were separated by electrophoresis in a 1.2% agarose gel, transferred to nylon membranes (Nytran; Schleicher & Schuell, Keene, NH, USA), and hybridized with 32 P-labeled probes specific for the individual chimeric transcripts encoded by the risk-stratifying translocations. The sequences of the probes used for Southern blotting are: ABL-P (5Ј GCC TAA GAC CCG GAG CTT TTC 3Ј), (4;11)-P (5Ј AGA GCA GAG CAA ACA GAA 3Ј), PBX-P (5Ј GAC CTG TCT CGG CCT CCC GAC TCC 3Ј), and AML-P (5Ј ACG CCT CGC TCA TCT TGC 3Ј). For the CML-and ALL-type t(9;22), a common c-ABL probe was used in the Southern blot, which does not allow differentiation between the subtypes of BCR-ABL message present. If this information is needed, the products can be rehybridized with individual oligonucleotide probes for the specific types of chimeric message.
Reverse dot-blot read-out
For the reverse dot-blot, the oligonucleotide probes listed in Table 1 were given a poly-T homopolymer tail, by using terminal deoxyribonucleotidyl transferase (TdT), and were then spotted on to a nylon membrane and covalently bound by ultraviolet radiation. 44, 45 Specifically, 200 pmoles of each oligonucleotide was tailed in a 100 l reaction containing 0.5 × TdT buffer containing 1 M potassium cacodylate (Boehringer Mannheim, Indianapolis, IN, USA), 1.25 mM TrisHCl, pH 7.4, 1 mM CoCl 2 , 0.2 mM DTT, and 0.8 mM dTTP. The reactions were incubated overnight at 37°C, and then terminated by the addition of 10 l of 10 mM EDTA. The resulting tailed oligonucleotide was at a concentration of 1 pmole/l.
A nylon membrane (Niodyne B membrane; Gibco BRL-Life Technologies, Grand Island, NY, USA) was placed on the convertible filtration manifold system which has a 96-well format (Gibco BRL-Life Technologies) and was then sealed. With the vacuum turned off, 100 l of TE (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0) was added to each well with a multichannel pipettor. For each spot, 5 l of probe (5 pmoles) was diluted in a total of 50 l of 0.01% Orange II dye (Sigma, St Louis, MO, USA) in TE. Sufficient quantities of each probe/dye solution were prepared to spot across an entire row of the membrane with that probe. A multichannel pipettor was used to pick up 50 l of each probe/dye solution from the 96-well plate and injected into a column on the manifold, and triturated into the TE solution already in the well. This procedure was repeated for all the columns on the manifold. The vacuum was then turned on, and the solution allowed to pass through the membrane. The membrane was removed from the manifold and placed on filter paper, and UV-irradiated to covalently link the probe to the membrane with a Stratalinker 2400 for a total exposure of 600 mJ/cm 2 . The membrane was then cut into strips that each contained a complete set of probes, and the strips were washed in 2.5 × SSPE (3.6 M NaCl, 200 mM NaH 2 PO 4 , 20 mM EDTA, pH 7.4)/0.1% SDS for 10-15 min at 55°C. At this point, strips can be hybridized immediately or dried and stored at room temperature in a desiccator. We have used strips up to 3 months after their preparation with no apparent diminution of signal.
For hybridization and detection, strips containing each of the hybridization probes were incubated in 3 ml of 5 × SSPE/0.5% SDS with agitation at 55°C for 5-10 min. Twenty l of each biotinylated PCR sample was added to a microfuge tube containing 20 l of denaturing solution (400 mM NaOH/80 mM EDTA) and the sample was allowed to denature for 5 min. The denatured products were then added to the strips, gently mixed by rocking, and incubated for 30 min at 55°C with mild agitation. The solution was then removed, and the strips rinsed with 3 ml of 2.5 × SSPE/0.1% SDS and washed for 10 min in 3 ml 2.5 × SSPE/0.1% SDS at 55°C. The solution was then removed from the strips and 3 ml of 2.5 × SSPE/0.1% SDS added to each strip followed by 10 l of streptavidin horseradish peroxidase solution (SHRP, 25 g/ml in 10 mM N-[2-acetamido]-2-aminoethanesulfonic acid, 200 mM NaCl, pH 6.5). Strips were then incubated for 10 min at room temperature with mild rocking. The solution was removed and the strips were rinsed and then washed in 3 ml of 2.5 × SSPE/0.1% SDS for 10 min at room temperature. The solution was decanted and the strips rinsed with 3 ml of 100 mM sodium citrate, pH 5.0, followed by a 10-min wash in 3 ml of the same solution. The sodium citrate was then decanted, and 3 ml of the color development solution added to each strip (150 l tetramethylbenzidine at 2 mg/ml, 3 l 3% hydrogen peroxide, 2.85 ml 100 mM sodium citrate). The strips were then rocked gently at room temperature (protected from light) for 15 min. The solution was then removed, and a RNA (1 g) extracted from positive controls, was serially diluted in 10-fold increments, then all dilutions were reverse transcribed and amplified in individual assays. Products were detected by Southern blot analysis with 32 P-labeled probes. b RNA from positive controls was serially diluted as above then analyzed using the multiplex RT-PCR assay. Products were detected either by Southern blot with 32 P-labeled probes or by a non-radioactive dot-blot assay.
the strips were rinsed for 5 min in water before being photographed.
Results
A number of different primer pairs have been described for RT-PCR amplification of the ALL risk-stratifying translocations t(9;22), t(1;19) t(4;11) and t(12;21). 25, 26, [46] [47] [48] [49] [50] [51] The use of various combinations of these primers in a single multiplex reaction results in a substantial decrease in the sensitivity of detection of the individual chimeric transcripts when compared to results obtained using the primers in individual reactions. 34, 35 This appears to result from inter-oligonucleotide competition between the various primers in the multiplex mixture. Thus, development of an efficient multiplex assay requires the redesign of oligonucleotide primers for each chimeric transcript and the determination of amplification conditions that minimize intra-and inter-nucleotide competition and nonspecific amplification. To accomplish this, we designed new oligonucleotide primer pairs for each individual translocation-enco-
Figure 5
Oligonucleotide probes are given Poly-T homopolymer tails with terminal deoxyribonucleotide transferase (TdT), then applied to a nylon membrane and covalently cross-linked to it. RNA is reverse transcribed into cDNA and PCR amplified with biotinylated primers. The PCR products are denatured, hybridized to the membranes, and nonspecifically bound product is washed off. The specifically bound PCR product is detected with strepavidin-peroxidase (S-P) followed by the addition of tetramethylbenedine. ded chimeric transcript that met the following criteria: (1) Each primer would have a T m for its complementary sequence between 52°C and 66°C. (2) The amplified products for each chimeric transcript should be of approximately the same size. (3) Minimal inter-primer and intra-primer annealing should occur. In addition, the design of these primers required the incorporation of new information on the structural features of recently characterized rare alternative chimeric transcripts that result from these translocations. 26, 52, 53 Individual pairs of primers were designed for the ALL-type t(9;22), CML-type t(9;22), t(1;19), and t(4;11), whereas a three primer set was a RNA extracted from 70 pediatric ALL samples was reverse transcribed and amplified in individual assays. Products were detected by Southern blot analysis with 32 P-labeled probes. b RNA from leukemic samples was analyzed by using the multiplex RT-PCR assay. Products from the multiplex assay were analyzed by either Southern blot with 32 P-labeled probes or a non-radioactive reverse dot-blot assay. c The number of discrepancies seen between the individual assay and the multiplex assay are indicated.
designed for the t(12;21) (Figures 1-4) . In the design of primers and probes for the CML-and ALL-type BCR-ABL chimeric transcripts, a common 3Ј c-ABL primer was developed. Because of the recent description of rare BCR-ABL transcripts with deletion of c-ABL exon 2 due to alternative splicing, it was essential to position this primer in exon 3. Similarly, the design of the primers for amplification of E2A-PBX1 required the repositioning of the 3Ј PBX1 primer to allow for amplification of the recently described alternative chimeric transcripts that result from more 3Ј breakpoints in PBX1 ( Figure  2) . 52, 53 The position of the 5Ј E2A primer was chosen to allow for amplification of transcripts that result from all described breakpoints in E2A. 7, 8, 52, 53 Similarly, the three primer set used for amplification of TEL-AML1 allowed detection of the chimeric transcripts encoded by all described breakpoints. 25, 26, 54 A total of 10 individual oligonucleotide primers were needed for the amplification of the chimeric transcripts encoded by these five different risk-stratifying translocations (Table 1 and Figures  1-4) .
To reduce the degree of suppression during the multiplex reaction, each component of the reaction mixture was optimized, including the concentration of dNTPs, MgSO 4 , the cosolvent DMSO, Taq polymerase, and the oligonucleotide primers. The most efficient amplification of all four chimeric products was achieved in 1 × PCR buffer containing 0.84 mM each dNTPs, 3.5 mM MgCl 2 , 5% DMSO, 10 U Taq polymerase, and the oligonucleotide primers, CML(9;22)5Ј, (4;11)5Ј, (4;11)3Ј each at a concentration of 0.75 ng/l and the primers ALL(9;22)5Ј, (9;22)3Ј, (1;19)5Ј, (1;19)3Ј, (12;21)5ЈA, (12;21)5ЈB (12;21)3Ј each at a concentration of 1.5 ng/l (see Table 1 ), respectively. Amplification cycle parameters were also optimized to minimize the amplification of nonspecific products in early cycles. This was accomplished by use of the so-called 'touchdown' hot start method, 55 as described in Materials and methods. Once oligonucleotides and conditions were optimized, 0.75 g of RNA from each of the positive controls was serially diluted in 10-fold increments in DEPC-treated water. Each dilution was then reverse transcribed and amplified for each translocation individually or in the new multiplex reaction. In the multiplex reaction, reverse transcription was performed with specific 3Ј oligonucleotide primers for each translocation product ( Table 1 ). The use of these specific RT primers resulted in a significant increase in sensitivity over that obtained when random hexamers were used for RT (data not shown). As shown in Table 2 , use of these optimized oligonucleotides and reaction conditions resulted in an equivalent or higher levels of sensitivity in the multiplex assays as compared to the individual RT-PCR reactions. Moreover, when using the multiplex assay, nearly equal levels of amplification were observed for each of the fusion products, as determined by Southern blot analysis (Figure 6 , below).
To significantly reduce the effort needed to identify an amplification product, we designed a reverse dot-blot detection system. As illustrated in Figure 5 , this approach involves covalently coupling specific oligonucleotide detection probes to a nylon membrane. This was accomplished by adding a poly-T homopolymer tail of approximately 400 nucleotides in length to the 3Ј end of each probe with TdT. To give added specificity to the read-out system, probes were designed that were 28-30 nucleotides in length prior to their tailing. Following the addition of the oligo dT tail, probes were denatured and spotted on to a nylon membrane through a vacuum manifold. Probes were then covalently coupled to the membrane by exposure to 600 mJ/cm 2 of ultraviolet light. The probes used in this reverse dot-blot were designed to have similar T m s so that hybridization and washing could be performed under uniform conditions. To detect the BCR/ABL fusion, individual probes were designed that distinguish between the p210 and p190 products.
To evaluate the performance of this multiplex assay, we analyzed diagnostic bone marrow aspirates from 41 selected pediatric ALL or CML patients, including five cases of ALL t(9;22), five cases of CML t(9;22), three cases of t(4;11), six cases of t(1;19), four cases of t(12;21), and 17 cases that lacked evidence of these translocations. Each case was analyzed by both the standard individualized RT-PCR reactions and by the multiplex reaction. Moreover, the amplified products from the multiplex reaction were detected by both gel electrophoresis/Southern blot and by the reverse dot-blot assay. Complete concordance was observed between the individual reactions and the multiplex assay, regardless of the read-out system used (these results represent a portion of those reported in Table 3 ). As an illustration, several positive cases were analyzed with the multiplex assay, and the PCR products were detected by gel electrophoresis/Southern blot ( Figure 6 ) or by reverse dot-blot (Figure 7) . While the reverse dot-blot took 3 h to obtain the results, the gel electrophoresis/Southern blot readout required an additional 36 h following amplification before a definitive result could be obtained.
Finally, we evaluated the feasibility of implementing this multiplex RT-PCR assay in the routine risk-assessment of pediatric ALL patients. Single and multiplex RT-PCR assays were performed in parallel on 29 consecutive pediatric ALL
Figures 6 and 7
RNA was extracted from the leukemic cell line HL60 and from primary leukemic blasts containing the indicated translocations (two patients with each translocation). RNA was analyzed by using the multiplex RT-PCR assay and the PCR products were detected by either Southern blot analysis with 32 P-labeled probes in current clinical use ( Figure 6 ) or the reverse dot-blot assay with newly designed 28 to 30-mer oligonucleotide probes (Figure 7) . A control lacking RNA was included, as were positive controls for each translocation (the latter were analyzed only by Southern blotting).
samples analyzed in the Molecular Pathology Laboratory at St Jude Children's Research Hospital. Again, identical results were obtained regardless of the RT-PCR assay and detection system used, indicating that this is a reliable method for the identification of these translocations (Table 3) .
Discussion
Current therapy for pediatric ALL requires the assessment of both clinical and laboratory features to accurately assign patients to specific therapeutic subgroups. Foremost among the laboratory features used to assign patients to individual risk groups are the presence of the recurrent translocations t(9;22), t(1;19), t(4;11), and t (12;21) . In this report, we now describe a multiplex RT-PCR assay coupled with a reverse dotblot read-out system that efficiently identifies the chimeric transcripts encoded by each of these risk-stratifying translocations. This assay contains a novel set of oligonucleotides primers that not only allows the reverse transcription and amplification of each of the translocation-encoded chimeric transcripts, but also provides a level of sensitivity similar to that achieved with standard individual reactions. Moreover, the reverse dot-blot read-out system employed was shown to be similar in sensitivity to Southern blotting coupled with the use of radioactive probes, yet required significantly less time and effort to achieve the same result. Analysis of 70 diagnostic leukemic samples and five leukemic cell lines resulted in a complete concordance between the results obtained with the multiplex assay and those obtained with standard individual RT-PCR assays. Thus, this multiplex assay represents an accurate and rapid means to identify these risk-stratifying genetic lesions in pediatric ALL.
In comparison to other published multiplex assays for pediatric ALL-associated translocations, our assay offers several advantages that make it ideal for the routine clinical evaluation of patients. First, it provides for the identification of the broadest range of risk-stratifying translocations among the assays of this type published to date. [34] [35] [36] 56 In addition to the high risk defining translocations, t(9;22), t(1;19), and t(4;11), our assay also accurately identifies patients whose leukemic blasts express the t(12;21)-encoded TEL-AML1 chimeric transcript. This subgroup of patients accounts for almost 25% of the total and confers an excellent prognosis when treated with modern therapeutic approaches. [25] [26] [27] [28] [29] [30] Indeed, accurate identification of this translocation at diagnosis may result in re-stratification of up to 25% of patients. Thus, the ability to detect TEL-AML1 in the routine diagnostic workup of pediatric ALL patients should provide a significant advance in patient stratification. Second, the design of oligonucleotides employed in our assay allow for the accurate identification of all of the described transcripts encoded by each of these translocations. 8, 25, 52, 53, 57, 58 This means that this combination of oligonucleotide primers and detection probes will allow for a more accurate identification of patients with these underlying molecular genetic lesions. Finally, the incorporation of a rapid non-radioactive read-out system for the detection of the amplified PCR products means this assay can be easily integrated into the clinical laboratory setting. The movement of this type of testing from the research setting into the clinical laboratory will accelerate the standardization of testing methods between laboratories, and in turn, will lead to a significant improvement in the ability to compare results between individual laboratories.
Although this multiplex assay is a significant improvement over previously published approaches, this assay still suffers from the inability to detect each of the high-risk associated MLL fusion transcripts that result from translocations affecting chromosome 11, band q23. Approximately 20 different chimeric MLL transcripts are predicted to result from these translocations in pediatric ALL. 19 Clearly, it would be impractical to incorporate RT-PCR reaction for each of these translocations into this multiplex assay. However, since most of these rearrangements occur in infants, and in this group of patients the t(4;11) accounts for greater than 80% of the lesions, this assay should serve as a useful first level screen for these prognostic markers. Coupling this multiplex assay with more direct approaches to assess the status of the MLL gene in infant patients could increase the percentage of patients that are accurately molecular genotyped for 11q23 risk-stratifying lesions.
In summary, we have developed a multiplex RT-PCR assay for the identification of the major risk-stratifying translocations of pediatric ALL. The characteristics of this assay suggest that its application to routine clinical screening will significantly improve the ability of clinical laboratories to accurately riskstratify pediatric ALL patients.
